FOR                                                         IMMEDIATE
RELEASE
18 November 2009


                       REGEN THERAPEUTICS PLC
              ("ReGen" or the "Company"; Ticker (RGT))

                      NOTICE OF GENERAL MEETING

The Company have today posted to shareholders a Notice of General
Meeting ("the Meeting") to grant authority to issue shares.  The
Meeting will be held at 11.00am on 7 December 2009 at the offices of
Alexander David Securities Limited, 10 Finsbury Square, London EC2A
1AD.   The Notice will be available on the website:
www.regentherapeutics.com
In the Notice, the Chairman wrote to Shareholders as follows:

"As the most recent  Interim figures show, ReGen  is not yet  trading
profitably and additional funds will  therefore be needed to  sustain
the Company until  such time  that it does  become profitable.    The
Directors are mindful of dilution and have drastically reduced  costs
wherever possible  including at  least halving  Directors  salaries.
Thus, so far this year the Company has raised £688,185 compared  with
£2.49m in 2007.

The Company has been encouraged at  the level of demand displayed  in
its recent share placings.  It also noted that the placings were with
long term investors  which the  Company believes has  meant that  the
share price has remained stable following the placings.  The  Company
has identified, from the placings  and from further conversations,  a
significant number of  potential additional long  term investors  who
are willing to further fund the Company to profitability.

With  regard  to   the  on-going  expansion   of  the   ColostrininTM
nutraceutical network, our  existing distributors  are continuing  to
work hard  to develop  their individual  markets. PRG  Nutraceuticals
Ltd,  the  most  recently   appointed  distributor,  launched   their
MemoryAid version  of the  product in  the UK  market at  the end  of
September. Unfortunately for ReGen it  inevitably takes a great  deal
of time from initiating discussions with potential new  distributors,
through the announcement of their appointment, their satisfying local
regulations prior to the commencement of sales, up until the point at
which revenues start to filter through to ReGen.  In past experience,
this process rarely takes less than six months and usually takes over
a year.

In consequence, whilst Shareholders may consider the lack of news  on
progress from the Company to be disappointing, in reality there is  a
great deal of  activity and a  huge effort being  made by the  entire
management team to  expedite the preparations  for product launch  in
each sector.

Therefore, to  continue  to  support the  Company's  development  and
return  to  Shareholders,  ReGen  is  seeking  to  renew  Shareholder
authority to take  in additional investment  to maintain the  capital
base into 2010. The Board  wishes to be able to  be in a position  to
consider promptly  and effect  appropriate funding  proposals as  and
when they occur  and is  therefore now seeking  to renew  Shareholder
authority to  be  able to  issue  new Ordinary  Shares  and/or  other
securities of the  Company to facilitate  future fundraisings  and/or
acquisitions of complementary businesses.   The Board are  requesting
authority to issue  up to  12,245,000 new Ordinary  Shares for  these
specific purposes, which represents approximately 33 per cent. of the
current issued share capital of the Company.

In  addition,  the  Board  is   seeking  renewal  of  their   general
authorities to  issue new  Ordinary Shares  and/or other  securities,
such general  authority being  last  granted to  them at  the  Annual
General Meeting of the  Company held on 21  July 2009. The Board  are
requesting authority to  issue up to  1,836,500 new Ordinary  Shares,
which represents  approximately 5  per cent.  of the  current  issued
share capital of the Company."

Contact:                                     Percy    Lomax,    ReGen
Therapeutics Plc Tel: 020 7153 4920
                                                  Roland     Cornish,
Beaumont Cornish Limited Tel: 020 7628 3396
                                                  David    Scott/Nick
Bealer, Alexander Securities Limited Tel: 020 7448 9820

---END OF MESSAGE---




This announcement was originally distributed by Hugin. The issuer is 
solely responsible for the content of this announcement.


Copyright © Hugin AS 2009. All rights reserved.